BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zuo Y, Xu H, Chen Z, Xiong F, Zhang B, Chen K, Jiang H, Luo C, Zhang H. 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells. Oncol Rep 2020;43:1928-44. [PMID: 32236631 DOI: 10.3892/or.2020.7563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Feng J, Meng X. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond. Front Pharmacol 2022;13:946811. [DOI: 10.3389/fphar.2022.946811] [Reference Citation Analysis]
2 Yang J, Song C, Zhan X. The role of protein acetylation in carcinogenesis and targeted drug discovery. Front Endocrinol 2022;13:972312. [DOI: 10.3389/fendo.2022.972312] [Reference Citation Analysis]
3 Nguyen HP, Tran Q, Nguyen CQ, Hoa TP, Duy Binh T, Nhu Thao H, Hue BTB, Tuan NT, Le Dang Q, Quoc Chau Thanh N, Van Ky N, Pham MQ, Yang SG. Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies. RSC Adv 2022;12:22108-18. [PMID: 36043105 DOI: 10.1039/d2ra01969h] [Reference Citation Analysis]
4 Firoozbakht F, Rezaeian I, Rueda L, Ngom A. Computationally repurposing drugs for breast cancer subtypes using a network-based approach. BMC Bioinformatics 2022;23:143. [PMID: 35443626 DOI: 10.1186/s12859-022-04662-6] [Reference Citation Analysis]
5 Altinok S, Sanchez-Hodge R, Stewart M, Smith K, Schisler JC. With or without You: Co-Chaperones Mediate Health and Disease by Modifying Chaperone Function and Protein Triage. Cells 2021;10:3121. [PMID: 34831344 DOI: 10.3390/cells10113121] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Li W, Wu H, Sui S, Wang Q, Xu S, Pang D. Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way. Front Cell Dev Biol 2021;9:736935. [PMID: 34595180 DOI: 10.3389/fcell.2021.736935] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Wawruszak A, Borkiewicz L, Okon E, Kukula-Koch W, Afshan S, Halasa M. Vorinostat (SAHA) and Breast Cancer: An Overview. Cancers (Basel) 2021;13:4700. [PMID: 34572928 DOI: 10.3390/cancers13184700] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
8 Han XL, Du J, Zheng YD, Dai JJ, Lin SW, Zhang BY, Zhong FB, Lin ZG, Jiang SQ, Wei W, Fang ZY. CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer. Biomed Res Int 2021;2021:5089371. [PMID: 33959656 DOI: 10.1155/2021/5089371] [Cited by in F6Publishing: 2] [Reference Citation Analysis]